| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/31/2023 | 32.31% | Morgan Stanley | $19 → $21.5 | Maintains | Overweight |
| 09/27/2023 | 53.85% | B. Riley Securities | $26 → $25 | Maintains | Buy |
| 09/26/2023 | 35.38% | Citigroup | $22 → $22 | Upgrades | Neutral → Buy |
| 09/25/2023 | 35.38% | Citigroup | → $22 | Upgrades | Neutral → Buy |
| 08/01/2023 | 60% | B. Riley Securities | $27 → $26 | Maintains | Buy |
| 07/27/2023 | 16.92% | Morgan Stanley | $19 → $19 | Reiterates | Overweight → Overweight |
| 07/26/2023 | 53.85% | Credit Suisse | → $25 | Reiterates | Outperform → Outperform |
| 06/21/2023 | 16.92% | Morgan Stanley | → $19 | Reiterates | Overweight → Overweight |
| 05/23/2023 | 10.77% | JP Morgan | → $18 | Initiates Coverage On | → Neutral |
| 05/22/2023 | 16.92% | Morgan Stanley | $24 → $19 | Maintains | Overweight |
| 04/27/2023 | 47.69% | Morgan Stanley | $26 → $24 | Maintains | Overweight |
| 03/20/2023 | -7.69% | Wolfe Research | → $15 | Upgrades | Underperform → Peer Perform |
| 02/15/2023 | 60% | B. Riley Securities | $27 → $26 | Maintains | Buy |
| 02/13/2023 | 35.38% | Citigroup | $16 → $22 | Maintains | Neutral |
| 01/18/2023 | 41.54% | Goldman Sachs | $18 → $23 | Maintains | Buy |
| 01/12/2023 | 60% | Morgan Stanley | $13.6 → $26 | Upgrades | Equal-Weight → Overweight |
| 01/04/2023 | 16.92% | B of A Securities | → $19 | Reinstates | → Neutral |
| 12/23/2022 | 66.15% | B. Riley Securities | $26 → $27 | Maintains | Buy |
| 12/16/2022 | 4.62% | UBS | → $17 | Initiates Coverage On | → Neutral |
| 11/02/2022 | -26.15% | Wolfe Research | → $12 | Downgrades | Peer Perform → Underperform |
| 10/26/2022 | -16.31% | Morgan Stanley | $14.5 → $13.6 | Maintains | Equal-Weight |
| 10/06/2022 | 16.92% | Goldman Sachs | $23 → $19 | Maintains | Buy |
| 09/28/2022 | 41.54% | Argus Research | $33 → $23 | Maintains | Buy |
| 09/27/2022 | 96.92% | B. Riley Securities | $37 → $32 | Maintains | Buy |
| 09/21/2022 | 53.85% | Credit Suisse | $30 → $25 | Maintains | Outperform |
| 07/27/2022 | -17.29% | GLJ Research | → $13.44 | Downgrades | Buy → Sell |
| 07/26/2022 | 127.69% | B. Riley Securities | $39 → $37 | Maintains | Buy |
| 07/26/2022 | 7.69% | Citigroup | $20 → $17.5 | Maintains | Neutral |
| 07/25/2022 | -10.77% | Morgan Stanley | $16 → $14.5 | Maintains | Equal-Weight |
| 07/21/2022 | 84.62% | Credit Suisse | $37 → $30 | Maintains | Outperform |
| 07/06/2022 | 140% | B. Riley Securities | $47 → $39 | Maintains | Buy |
| 07/06/2022 | -1.54% | Morgan Stanley | $24 → $16 | Maintains | Equal-Weight |
| 06/14/2022 | 127.69% | JP Morgan | $43 → $37 | Maintains | Overweight |
| 05/31/2022 | 66.15% | Goldman Sachs | $36 → $27 | Maintains | Buy |
| 05/11/2022 | 47.69% | Morgan Stanley | $23.5 → $24 | Maintains | Equal-Weight |
| 04/25/2022 | 189.23% | B. Riley Securities | $46 → $47 | Maintains | Buy |
| 03/28/2022 | 183.08% | B. Riley Securities | $37 → $46 | Maintains | Buy |
| 03/24/2022 | 170.77% | JP Morgan | $37 → $44 | Maintains | Overweight |
| 03/22/2022 | 90.77% | Goldman Sachs | $27 → $31 | Maintains | Buy |
| 01/11/2022 | 41.54% | Wolfe Research | → $23 | Downgrades | Outperform → Peer Perform |
| 11/29/2021 | 44.62% | Morgan Stanley | $22.5 → $23.5 | Maintains | Equal-Weight |
| 11/17/2021 | 84.62% | Wolfe Research | → $30 | Initiates Coverage On | → Outperform |
| 10/26/2021 | 38.46% | Morgan Stanley | $21 → $22.5 | Maintains | Equal-Weight |
| 10/06/2021 | 47.69% | Goldman Sachs | $26 → $24 | Upgrades | Neutral → Buy |
| 08/11/2021 | 60% | Morgan Stanley | → $26 | Initiates Coverage On | → Equal-Weight |
| 07/08/2021 | 60% | Argus Research | → $26 | Initiates Coverage On | → Buy |
| 06/16/2021 | 140% | JP Morgan | → $39 | Initiates Coverage On | → Overweight |
| 05/04/2021 | 47.69% | Credit Suisse | $21 → $24 | Upgrades | Neutral → Outperform |
| 04/26/2021 | — | Keybanc | Downgrades | Overweight → Sector Weight | |
| 04/19/2021 | 18.15% | Exane BNP Paribas | → $19.2 | Downgrades | Outperform → Neutral |
| 04/12/2021 | — | Goldman Sachs | Initiates Coverage On | → Neutral | |
| 04/09/2021 | 23.08% | Goldman Sachs | → $20 | Initiates Coverage On | → Neutral |
| 03/08/2021 | 23.08% | Keybanc | $22 → $20 | Maintains | Overweight |
| 01/26/2021 | -4.62% | GLJ Research | $15.75 → $15.5 | Downgrades | Buy → Hold |
| 01/19/2021 | 37.23% | Exane BNP Paribas | → $22.3 | Upgrades | Neutral → Outperform |
| 01/19/2021 | 23.08% | KeyBanc | $17 → $20 | Maintains | Overweight |
| 12/22/2020 | 4.62% | Keybanc | $14 → $17 | Maintains | Overweight |
| 12/01/2020 | -13.85% | Keybanc | $12 → $14 | Maintains | Overweight |
| 11/24/2020 | -3.08% | GLJ Research | $6.2 → $15.75 | Upgrades | Hold → Buy |
| 11/20/2020 | -26.15% | Keybanc | → $12 | Upgrades | Sector Weight → Overweight |
| 09/16/2020 | -67.69% | Credit Suisse | $4.75 → $5.25 | Maintains | Neutral |
| 04/15/2020 | — | Credit Suisse | Reinstates | → Neutral | |
| 03/30/2020 | -75.38% | Goldman Sachs | → $4 | Reinstates | → Neutral |
| 03/24/2020 | -32.31% | B. Riley Securities | $10 → $11 | Maintains | Buy |
| 03/04/2020 | -63.08% | Citigroup | $8 → $6 | Maintains | Neutral |
| 02/20/2020 | -38.46% | CFRA | $9 → $10 | Reiterates | → Strong Buy |
| 01/10/2020 | — | Citigroup | Downgrades | Buy → Neutral | |
| 01/09/2020 | -32.31% | B. Riley Securities | $12 → $11 | Maintains | Buy |
| 10/24/2019 | -26.15% | B. Riley Securities | $13 → $12 | Maintains | Buy |
| 10/01/2019 | -20% | B. Riley Securities | $16 → $13 | Maintains | Buy |
| 09/23/2019 | -50.77% | JP Morgan | $14 → $8 | Downgrades | Overweight → Neutral |
| 09/11/2019 | -26.15% | Credit Suisse | $14 → $12 | Maintains | Outperform |
| 09/04/2019 | -50.77% | Citigroup | $10 → $8 | Maintains | Buy |
| 04/26/2019 | -13.85% | Credit Suisse | $13 → $14 | Upgrades | Neutral → Outperform |
| 01/09/2019 | -47.69% | Cowen & Co. | → $8.5 | Initiates Coverage On | → Market Perform |
| 12/03/2018 | -20% | Citigroup | $15 → $13 | Maintains | Buy |
What is the target price for Cleveland-Cliffs (CLF)?
The latest price target for Cleveland-Cliffs (NYSE: CLF) was reported by Morgan Stanley on October 31, 2023. The analyst firm set a price target for $21.50 expecting CLF to rise to within 12 months (a possible 32.31% upside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cleveland-Cliffs (CLF)?
The latest analyst rating for Cleveland-Cliffs (NYSE: CLF) was provided by Morgan Stanley, and Cleveland-Cliffs maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Cleveland-Cliffs (CLF)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cleveland-Cliffs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cleveland-Cliffs was filed on October 31, 2023 so you should expect the next rating to be made available sometime around October 31, 2024.
Is the Analyst Rating Cleveland-Cliffs (CLF) correct?
While ratings are subjective and will change, the latest Cleveland-Cliffs (CLF) rating was a maintained with a price target of $19.00 to $21.50. The current price Cleveland-Cliffs (CLF) is trading at is $16.25, which is out of the analyst's predicted range.